載入...
Cholesterol Ester Transfer Protein Inhibitor Review
Treatment of blood cholesterol is part of a strategy to lower atherosclerotic cardiovascular (ASCVD) risk. While use of HMG-CoA reductase inhibitors to modify cholesterol levels is the primary means of lowering the risk of an ASCVD event, residual risk remains. A new strategy being investigated is t...
Na minha lista:
| 發表在: | Hosp Pharm |
|---|---|
| Main Authors: | , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
SAGE Publications
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5735735/ https://ncbi.nlm.nih.gov/pubmed/29276295 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0018578717729669 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|